NMIBC
22 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05375903) | UroGen Pharma Ltd. | 2022-06-01 |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05014139) | Astellas Pharma Global Development, Inc. | 2021-12-07 |
| A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NCT07505615) | Ding-Wei Ye | 2021-10-12 |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors (NCT03914794) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-10-02 |
| ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer (NCT06810141) | ImmunityBio, Inc. |
Track NMIBC automatically
Every clearance here is in the API, with alerts when new ones post.